Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2015’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Attention Deficit Hyperactivity Disorder (ADHD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Attention Deficit Hyperactivity Disorder (ADHD) Overview
Therapeutics Development
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview
Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies
Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes
Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development
Alcobra Ltd
Amarantus Bioscience Holdings, Inc.
Arbor Pharmaceuticals, LLC.
Cerecor Inc.
Collegium Pharmaceutical, Inc.
Curemark, LLC
DURECT Corporation
Eli Lilly and Company
H. Lundbeck A/S
Hisamitsu Pharmaceutical Co., Inc.
Integrative Research Laboratories Sweden AB
Intra-Cellular Therapies, Inc.
KemPharm, Inc.
Merck & Co., Inc.
Mnemosyne Pharmaceuticals, Inc.
Neos Therapeutics, Inc.
NeuroDerm Ltd.
Otsuka Holdings Co., Ltd.
P2D Bioscience
Polleo Pharma Limited
Reviva Pharmaceuticals Inc.
Samyang Biopharmaceuticals Corporation
Shire Plc
Signature Therapeutics, Inc
Sunovion Pharmaceuticals Inc.
Supernus Pharmaceuticals, Inc.
Taisho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Tris Pharma, Inc.
Vernalis Plc
Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(nicotine + opipramol hydrochloride) - Drug Profile
amfetamine XR - Drug Profile
AR-08 - Drug Profile
BLI-1008 - Drug Profile
BNC-375 - Drug Profile
brexpiprazole - Drug Profile
centanafadine IR - Drug Profile
centanafadine SR - Drug Profile
CM-4612 - Drug Profile
CTX-1301 - Drug Profile
CTX-1302 - Drug Profile
dasotraline - Drug Profile
dextroamphetamine - Drug Profile
dextroamphetamine MR - Drug Profile
Drug for Attention Deficit Hyperactivity Disorder - Drug Profile
edivoxetine - Drug Profile
eltoprazine - Drug Profile
etiguanfacine - Drug Profile
guanfacine hydrochloride ER - Drug Profile
HTL-1071 - Drug Profile
IRL-752 - Drug Profile
ITI-214 - Drug Profile
KP-415 CR - Drug Profile
lisdexamfetamine dimesylate - Drug Profile
Metadoxine ER - Drug Profile
methylphenidate - Drug Profile
methylphenidate hydrochloride - Drug Profile
methylphenidate hydrochloride - Drug Profile
methylphenidate hydrochloride SR - Drug Profile
methylphenidate hydrochloride XR - Drug Profile
MGS-0028 - Drug Profile
molindone hydrochloride ER - Drug Profile
PBF-509 - Drug Profile
PD-2005 - Drug Profile
PD-2007 - Drug Profile
PFR-08001 - Drug Profile
PFR-8026 - Drug Profile
RP-5063 - Drug Profile
SHP-465 - Drug Profile
Small Molecule for ADHD - Drug Profile
Small Molecules for Attention Deficit Hyperactivity Disorder - Drug Profile
Small Molecules to Agonize NMDA2D for ADHD - Drug Profile
Small Molecules to Antagonize H3 Receptor for ADHD And Alzheimer's Disease - Drug Profile
Small Molecules to Inhibit COMT for Cognitive Disorders - Drug Profile
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile
Small Molecules to Modulate Choline Transporter for ADHD - Drug Profile
TAK-137 - Drug Profile
TRI-102 - Drug Profile
V-81444 - Drug Profile
viloxazine hydrochloride - Drug Profile
vortioxetine hydrobromide - Drug Profile
Attention Deficit Hyperactivity Disorder (ADHD) - Recent Pipeline Updates
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Arbor Pharmaceuticals, LLC., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cerecor Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark, LLC, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corporation, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Integrative Research Laboratories Sweden AB, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Intra-Cellular Therapies, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co., Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Mnemosyne Pharmaceuticals, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Polleo Pharma Limited, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Samyang Biopharmaceuticals Corporation, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Signature Therapeutics, Inc, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma, Inc., H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Vernalis Plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Recent Pipeline Updates, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects, H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..1), H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..2), H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..3), H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects (Contd..4), H1 2015
Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2015
Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook